Evidence map›Paper›PMID 28035772›Full record

ArticleHepatology (Baltimore, Md.)2017

Deregulated neddylation in liver fibrosis.

Imanol Zubiete-Franco, Pablo Fernández-Tussy, Lucía Barbier-Torres, Jorge Simon, David Fernández-Ramos, Fernando Lopitz-Otsoa, Virginia Gutiérrez-de Juan, Sergio López de Davalillo, Antonio Martín Duce, Paula Iruzubieta and 12 more

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Hepatology (Baltimore, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. A Review of CXCL1 in Cardiac Fibrosis.Frontiers in cardiovascular medicine · 2021
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Role of neddylation in diabetes metabolism: potential therapeutic target.Journal of diabetes and metabolic disorders · 2026
    Review
  6. Conjugated bile acid-driven CD14JHEP reports : innovation in hepatology · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Neddylation steers the fate of cellular receptors.Experimental & molecular medicine · 2024
    Review
  14. Article
  15. Article
  16. Protein neddylation and its role in health and diseases.Signal transduction and targeted therapy · 2024
    Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 3 countries.

Imanol Zubiete-FrancoCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
Pablo Fernández-TussyCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
Lucía Barbier-TorresCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
Jorge SimonCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
David Fernández-RamosCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
Fernando Lopitz-OtsoaCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
Virginia Gutiérrez-de JuanCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
Sergio López de DavalilloCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
Antonio Martín DuceNursery Department, University of Alcalá, Madrid, Spain.
Paula IruzubietaGastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, Santander, Spain.
Daniel TaiboCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
Javier CrespoGastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, Santander, Spain.
Juan CaballeriaLiver Unit, Hospital Clínic, CIBERehd, IDIBAPS, Barcelona, Spain.
Erica VillaDepartment of Gastroenterology, University Hospital of Modena & University of Modena and Reggio Emilia, Modena, Italy.
Igor AurrekoetxeaDepartment of Physiology, University of the Basque Country UPV/EHU, Faculty of Medicine and Dentistry, Leioa, Spain, and Biocruces Health Research Institute, Barakaldo, Spain.
Patricia AspichuetaDepartment of Physiology, University of the Basque Country UPV/EHU, Faculty of Medicine and Dentistry, Leioa, Spain, and Biocruces Health Research Institute, Barakaldo, Spain.
Marta Varela-ReyCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
Shelly C LuDivision of Digestive Liver Disease, Cedars-Sinai Medical Center, Los Angeles, CA.
José M MatoCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
Naiara BerazaCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
Teresa C DelgadoCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
María L Martínez-ChantarCenter for Cooperative Research in Bioscience (CIC bioGUNE), CIBERehd, Derio, Bizkaia, Spain.
Centro de Investigación Biomédica en Red · ESCIC bioGUNE · ESMarqués de Valdecilla University Hospital · ESBioCruces Health research Institute · ESCedars-Sinai Medical Center · USCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESUniversidad de Alcalá · ESUniversity of Modena and Reggio Emilia · ITUniversity of the Basque Country · ES

Funding

USC RESEARCH CENTER FOR LIVER DISEASES: PILOT PROGRAMSP30DK048522 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAPLOWITZ, NEIL · 1995 to 2020
$21.8M
Role of SAMe in Pathogenesis and Treatment of Non-Alcholic Fatty Liver DiseaseR01AT001576 · NCCIH · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LU, SHELLY CHI-LOO · 2002 to 2018
$5.0M
PROHIBITIN 1 IN LIVER INJURY AND CANCERR01CA172086 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LU, SHELLY CHI-LOO · 2014 to 2018
$1.6M
NCCIH NIH HHS R01 AT001576NCI NIH HHS R01 CA172086NIDDK NIH HHS P30 DK048522
6 · The paper itself

Abstract

Hepatic fibrosis is a global health problem currently without effective therapeutic approaches. Even though the ubiquitin-like posttranslational modification of neddylation, that conjugates Nedd8 (neural precursor cell expressed developmentally downregulated) to specific targets, is aberrant in many pathologies, its relevance in liver fibrosis (LF) remained unexplored. Our results show deregulated neddylation in clinical fibrosis and both in mouse bileductligation- and CCl

conclusionNeddylation inhibition reduces fibrosis, suggesting neddylation as a potential and attractive therapeutic target in liver fibrosis. (Hepatology 2017;65:694-709).

Indexed as

AgingAnalysis of VarianceAnimalsApoptosisBiopsy, NeedleCell ProliferationCells, CulturedCell SurvivalChemokine CCL4ChemokinesCyclopentanesDisease Models, AnimalHepatic Stellate CellsHumansImmunohistochemistryLiver CirrhosisChemokine CCL4ChemokinesCyclopentanesNEDD8 ProteinNedd8 protein, mousepevonedistatPyrimidinesUbiquitins

Identifiers

PMID28035772
PMCPMC5258821
OpenAlexW2565679277

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.